Opioid-induced constipation (OIC) is projected to hit $2.8 billion by 2022, according to Credence Research (March 2016 report). Growth for this market will come from the introduction of several new drugs, including this sponsor’s compound, which would be the first to market in a new class.
We make gastroenterology trials less painful…and easier to digest.
Our success is a combination of aligning the enrollment process with today’s realities, customized solutions, and true insight into site relationships. From OIC/OIBD, IBS and GERD, to Crohn’s disease, Acurian makes trials a lot less trying.
Acurian is the leader in the patient recruitment and retention industry.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.